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The prognosis of stented lesions differs according to in-stent neointimal characteristics on
optical coherence tomography (OCT). In particular, patients who show in-stent heteroge-
neous neointima are associated with a higher incidence of target lesion revascularization
(TLR) compared with those who show in-stent non-heterogeneous neointima. However, the
relationship between in-stent neointimal characteristics and native coronary atherosclerosis
progression has not been clearly elucidated. The study aimed to investigate the relationship
between in-stent neointimal characteristics and progression of native atherosclerosis.
Methods
The neointimal characteristics of 377 patients with 377 drug-eluting stents (DESs) were
quantitatively and qualitatively assessed using OCT. The OCT-based neointima was cate-
gorized as homogeneous (n = 207), heterogeneous (n = 93), and layered (n = 77). The rela-
tionship of non-target lesion revascularization (non-TLR) with neointimal characteristics was
evaluated after OCT examination of the stents.
Results
After a median follow-up duration of 40.0 months, patients with heterogeneous neointima
showed significantly higher non-TLR rates than those with homogeneous neointima and
tended to have higher non-TLR rates than those with layered neointima (heterogeneous vs.
homogeneous:14.0% vs. 8.7%, p = 0.046; heterogeneous vs. layered neointima:14.0% vs.
7.8%, p = 0.152). Multivariate analysis showed that the independent determinants for non-
TLR were heterogeneous neointima (HR: 2.237, 95% CI: 1.023–4.890, p = 0.044) and
chronic kidney disease (hazard ratio [HR]: 8.730, 95% CI: 2.175–35.036, p = 0.002).
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Conclusions
The heterogeneous neointima in DES-treated lesions was associated with a higher inci-
dence of non-TLR and target lesion failure. This finding suggests that the neointimal pattern
may reflect the progression of the native lesion.
Introduction
The prognosis of stented lesions may differ according to the in-stent neointimal characteristics
observed on optical coherence tomography (OCT) [1–3]. In particular, patients who show in-
stent heterogeneous neointimal growth are associated with a higher incidence of target lesion
revascularization (TLR) compared with those who show in-stent non-heterogeneous neointi-
mal growth [1, 2]. However, the relationship between in-stent neointimal characteristics and
native coronary atherosclerosis progression has not been clearly elucidated. Therefore, in this
study, we aimed to this study to investigate the relationship between in-stent neointimal char-
acteristics and native atherosclerosis progression in untreated coronary segments using OCT




Among 540 patients with 576 stented lesions from the Yonsei OCT registry (Clinical Trials.
gov NCT02099162), 163 patients were excluded from the study for the following reasons: 1)
inadequate OCT image quality (n = 5), 2) index PCI with bare metal stents (n = 45), 3) OCT
for two or more stented lesions (n = 36), 4) OCT after balloon angioplasty due to tight lesion
(n = 5), 5) OCT-based evidence of neoatherosclerotic lesions (n = 39), 6) in-stent restenosis
(ISR) lesions treated with a DES (n = 30) and 7) loss to follow-up (n = 3). Finally, 377 patients
with 377 DES-treated lesions were included. The stent type was selected at the discretion of the
physician at the time of index PCI. Among the patients included, 127 first-generation DESs
and 250 second-generation DESs were used. A first-generation DES was defined as a siroli-
mus- (Cypher) and paclitaxel- (Taxus) eluting stent, and the second-generation DESs were
defined as zotarolimus-(Endeavor Sprint or Resolute), everolimus- (Xience), and biolimus-
(Nobori) eluting stents. DES implantation was performed using conventional techniques.
Unfractionated heparin at 100 IU/kg was administered as an initial bolus, with additional
boluses administered during the procedure to achieve an activated clotting time of 250–300 s.
Dual antiplatelet therapy (100 mg aspirin and 75 mg clopidogrel, 180 mg ticagrelor or 10 mg
prasugrel) was recommended for all patients for at least 12 months after DES implantation.
Follow-up coronary angiography (CAG) and OCT were performed for evidence of myocardial
ischemia in the stress test or clinical presentation of coronary artery disease (n = 84, 22.3%) or
routine follow-up angiography (n = 293, 77.7%). Drug-coated balloon (DCB) angioplasty was
performed for 80 patients who presented with ISR lesions, defined as lesions with diameter
stenosis� 70% on quantitative coronary analysis (QCA) or diameter stenosis� 50% with the
evidence of myocardial ischemia at the time of OCT. DCB angioplasty was not performed for
lesions not consistent to ISR. When DCB angioplasty was required for the ISR lesions, OCT
was performed before and after DCB angioplasty. The study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki. The Institutional Review Board of Severance
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Analysis of coronary angiography and OCT images
QCA was performed using an offline computerized QCA system (CAAS System; Pie Medical
Imaging, Maastricht, The Netherlands) in an independent core laboratory (Cardiovascular
Research Center, Seoul, Korea). OCT was performed using the C7-XR imaging system (Light-
Lab Imaging; St. Jude Medical, St. Paul, MN, USA). All OCT images were analyzed using a cer-
tified offline software (QIvus; Medis Medical Imaging System, Leiden, The Netherlands) at a
core laboratory (Cardiovascular Research Center) by analysts who were blinded to both the
clinical and angiographic information. The cross-sectional OCT images were measured at
1-mm intervals for quantitative assessments. The stent and luminal cross-sectional area (CSA)
were analyzed, and the neointimal CSA was calculated as the stent CSA minus the luminal
CSA. The segment with minimal lumen area (MLA) and maximal neointimal proliferation
was considered the representative site of lesions for future clinical follow-up [1, 2]. Therefore,
the stented segments at the minimal lumen CSA and maximal neointimal CSA were qualita-
tively assessed to characterize the neointimal tissue as either homogeneous (a uniform signal-
rich band without focal variation or attenuation), heterogeneous (focally changing optical
properties and various backscattering patterns), or layered neointima (layers with different
optical properties, namely, an adluminal high-scattering layer and an abluminal low-scattering
layer) [4]. Neoatherosclerosis was defined as a lipid neointima (including a thin-cap
fibroatheroma neointima, defined as a fibroatheroma with a fibrous cap<65 μm) or calcified
neointima [5]. Although the OCT pattern had one of the three neointimal patterns (homoge-
neous, heterogeneous, or layered pattern) with at least one OCT feature of neoatherosclerosis,
we classified it as neoatherosclerosis and excluded it from the current study. The neointimal
morphologic characteristics were qualitatively evaluated by 2 observers who were blinded to
the patients’ clinical data and angiographic results. Inter- and intra-observer agreements for
the assessment of the neointimal tissue characteristics in our core laboratory have been
reported previously [6].
DCB angioplasty and periprocedural OCT
All 80 patients who underwent DCB angioplasty at the time of OCT received 100 mg aspirin
and 300 mg clopidogrel, 180 mg, ticagrelor or 60 mg prasugrel as the loading dose at 12 hours
before DCB angioplasty. After diagnosis of ISR on angiography, pre-interventional OCT was
performed before plain balloon dilation. Subsequently, paclitaxel-coated balloon (Sequent
Please; B. Braun, Melsungen, Germany) was used for DCB angioplasty. The DCB size was
determined based on the lesion length and stent diameter of ISR. The DCB was inflated for 60
seconds at the ISR lesion. Post-interventional OCT evaluation was conducted after DCB angio-
plasty. Dual anti-platelet (100 mg aspirin and 75 mg clopidogrel, 180 mg ticagrelor or 10 mg
prasugrel) was prescribed for at least 1 month after DCB angioplasty.
Follow-up
Events were assessed with a pre-specified protocol. All events were collected using a web-based
reporting system. Additional information was obtained by medical records or telephone con-
tact. The main endpoint was the incidence of non-target lesion revascularization (non-TLR)
assessed according to the neointimal characteristics The TLR rate and any revascularization
and myocardial infarction (MI) events were evaluated. TLR was defined as any repeat percuta-
neous intervention of the target lesion (including 5 mm proximal and 5 mm distal to the target
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lesion) or surgical bypass of the target vessel performed for restenosis or other complications
involving the target lesion. In this study, DES-treated lesions subjected to OCT were the target
lesions. All lesions, except for DES-treated lesions subjected to OCT evaluation, were defined
as non-target lesions [7]. MI was defined according to the third universal definition [8].
Statistical analysis
Data are expressed as the number (%), mean ± standard deviation or median (interquartile
range). Categorical data were compared using the chi-square test or Fisher’s exact test. Contin-
uous variables were compared using the Student’s t-test for normally distributed data and
Kruskal-Wallis H test for non-normally distributed data. Event-free survival was analyzed
using the Kaplan-Meier survival curves and compared using the log-rank test between differ-
ent groups. Using univariate Cox proportional hazards regression analysis, we analyzed 16
probable risk factors including age, sex, conventional cardiac risk factors, medication, stent
generation, DCB angioplasty and neointimal characteristics. Age, sex and the variables with p-
value <0.10 in the univariate analysis were included in the multivariate analysis to determine
the independent predictors for revascularization. Univariate analysis using logistic regression
was performed to identify independent predictors of the heterogeneous neointima formation.
Age, sex and the variables with p-value less than 0.10 were entered in the multivariate analysis.
A p-value <0.05 was considered statistically significant. Statistical analyses were performed
using SPSS version 20.0.0 (IBM, Armonk, NY, USA).
Results
Baseline characteristics, angiography features, and QCA
The median duration between index PCI and OCT examination was 9.0 months (interquartile
range: 6.0–13.5 months). CAG and OCT were performed for an evidence of ischemia or recur-
rent chest pain in 84 patients (acute coronary syndrome: 26 and stable angina: 58) and for rou-
tine follow up in 293 patients. DCB angioplasty was performed for 80 ISR lesions of the 377
stented lesions. The baseline, angiographic, and OCT characteristics of the patients according
to the neointimal characteristics are shown in Table 1 [homogeneous (n = 207), heterogeneous
(n = 93), and layered neointima (n = 77) (Table 1)].
Significant differences were not found over time from index PCI to OCT evaluation and
over the clinical follow-up durations among the 3 neointima groups. The overall baseline and
angiographic characteristics were comparable among the 3 neointimal groups. The patients in
the heterogeneous and layered neointima groups were older than those in the homogeneous
neointima group (p = 0.020). Although significant differences were not observed in the stent
diameter and stent length, the heterogeneous and layered neointima groups had significantly
greater diameter stenosis in QCA than the homogenous neointima group. In quantitative
OCT analysis, the heterogeneous and layered neointima groups showed significantly smaller
MLA than the homogenous neointima group. Based on the QCA and OCT results, DCB
angioplasty was more frequently performed in the heterogeneous and layered neointima
groups than in the homogenous neointima group (p<0.001).
In the QCA analysis at the time of OCT for non-TLR during the follow-up period, MLD
and diameter stenosis were not different among the 3 neointimal groups. However, non-
TLR developed significantly earlier in the heterogeneous neointima group than in the non-het-
erogeneous neointima group (mean duration from OCT to non-TLR: homogeneous vs. het-
erogeneous vs. layered 60.89 ± 30.56 vs. 32.92 ± 26.38 vs. 43.33 ± 33.96 months, p = 0.043; S1
Table).
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Clinical outcomes
The median clinical follow-up duration after OCT examination was 40.0 months (interquartile
range: 20.0–54.5 months). The incidence of TLR and any revascularization differed signifi-
cantly according to the neointimal characteristics (p<0.001). The TLR rate was higher in order
of the heterogeneous, layered, and homogeneous neointima groups; the differences in the TLR
rates of each group were significant (homogeneous vs. heterogeneous vs. layered neointima:
Table 1. Comparison of the baseline, angiographic, and OCT characteristics according to the neointimal characteristics.
Variables Homogeneous neointima Heterogeneous neointima Layered neointima p-value
n = 207 (54.9%) n = 93 (24.7%) n = 77 (20.4%)
Time from index PCI to OCT, months 15.2 ± 18.1 18.4± 24.5 19.7 ± 22.0 0.191
Duration of clinical follow-up, months 39.5 ± 22.4 37.9 ± 22.1 41.5 ± 20.9 0.566
Clinical characteristics
Age, years 61.2 ± 9.7 63.6 ± 8.7 64.3 ± 8.6 0.020
Male sex 138 (66.7) 63 (67.7) 60 (77.9) 0.177
Diabetes 63(30.4) 34 (36.6) 34 (44.2) 0.089
Hypertension 124 (59.9) 55 (59.1) 55 (71.4) 0.164
Dyslipidemia 99 (47.8) 36 (38.7) 39 (50.6) 0.231
Current smoker 41 (19.8) 23 (24.7) 24 (31.2) 0.124
History of MI 3 (1.4) 4 (4.3) 4 (5.2) 0.164
CKD 2 (1.0) 3 (3.2) 0 (0) 0.149
Beta blocker 171 (82.6) 67 (72.0) 60 (77.9) 0.111
ACEi or ARB 145 (70.0) 64 (68.8) 54 (70.1) 0.974
Statin 190 (91.8) 84 (90.3) 68 (88.3) 0.661
Angiographic profiles
Target vessel 0.079
LAD 116 (56.0) 56 (60.2) 44 (57.1)
LCX 49 (23.7) 14 (15.1) 9 (11.7)
RCA 42 (20.3) 23 (24.7) 24 (31.2)
Stent types 0.506
First-generation DES 75 (36.2) 29 (31.2) 23 (29.9)
Second-generation DES 132 (63.8) 64 (68.8) 54 (70.1)
Stent diameter, mm 2.98± 0.33 3.05 ± 0.36 3.07 ± 0.40 0.088
Stent length, mm 23.9 ± 6.3 22.2 ± 6.9 23.7 ± 6.1 0.099
Preinterventional QCA
Diameter stenosis, % 27.0 ± 23.2 46.6 ± 31.7 50.6 ± 28.6 <0.001
Lesion length, mm 17.1 ± 6.0 16.5 ± 7.0 15.0 ± 7.6 0.529




MLA, mm2 4.63 ± 1.66 4.13 ± 2.06 3.93 ± 2.11 0.007
MSA, mm2 5.11 ± 1.71 4.83 ± 1.47 4.88 ± 1.59 0.806
Mean NIH area, mm2 1.41 ± 1.03 1.20 ± 0.77 1.41 ± 0.92 0.224
Data are presented as mean ± standard deviation or number (%). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic
kidney disease; DCB, drug-coated balloon; DES, drug-eluting stent; LAD, left anterior descending artery; LCX, left circumflex artery; MI, myocardial infarction; MLA,
minimal lumenarea; MSA, minimal stent area; NIH, neointimal hyperplasia; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; QCA,
quantitative coronary angiography analysis; RCA, right coronary artery.
https://doi.org/10.1371/journal.pone.0247359.t001
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2.9% vs. 19.4% vs. 10.4%, p<0.001; Fig 1A). The heterogeneous neointima group showed sig-
nificantly higher non-TLR rate than the homogeneous neointima group and tended to have
higher non-TLR rates than the layered neointima group (homogeneous vs. heterogeneous
intima: 8.7% vs. 14.0%, p = 0.046; heterogeneous vs. layered neointima: 14.0% vs. 7.8%,
p = 0.152; Table 2, Fig 1B). The heterogeneous neointima group had significantly higher any
revascularization rate than the homogeneous and layered neointima groups (homogeneous vs.
heterogeneous intima: 10.6% vs. 30.1%, p<0.001; heterogeneous vs. layered neointima: 30.1%
vs. 13.0%, p = 0.003; Fig 1C).
TLR (36.7%) and non-TLR (23.3%) were more frequently observed in the patients who
underwent DCB angioplasty in the heterogeneous neointima group (Fig 2A and 2B).
Subgroup analysis according to the reason for follow-up angiography was shown in S2
Table. The incidence of DCB angioplasty, heterogeneous neointima, any MI and TLR were sig-
nificantly higher in group with an evidence of ischemia for follow-up angiography. However,
there was no significant difference in the incidence of NTLR between group with an evidence
of ischemia for follow-up angiography and routine follow-up angiography.
Multivariate analysis showed that heterogeneous neointima (HR: 2.237, 95% confidence
interval [CI]: 1.023–4.890, p = 0.044) and chronic kidney disease (hazard ratio [HR]: 8.730,
95% CI: 2.175–35.036, p = 0.002) independently increased the non-TLR incidence (Table 3).
Heterogeneous neointima (HR: 2.671, 95% CI: 1.261–5.656, p = 0.010) and chronic kidney
disease (HR: 5.971, 95% CI: 1.902–18.751, p = 0.002) were the independent predictors of any
revascularization (Table 4). In addition, the significant predictor for the heterogeneous neoin-
tima was MI at the time of OCT (HR: 6.698, 95% CI: 1.212–37.022, p = 0.029) (S3 Table).
Fig 1. Kaplan-Meier curves for the target lesion revascularization rate (A), non-target lesion revascularization rate (B),
and any revascularization rate (C) according to the neointimal characteristics.
https://doi.org/10.1371/journal.pone.0247359.g001
Table 2. Clinical adverse events according to the neointimal characteristics at 40.0 months after OCT evaluation.
Homogeneous neointima Heterogeneous neointima Layered neointima p-value
n = 207 (54.9%) n = 93 (24.7%) n = 77 (20.4%)
Non-TLR 18 (8.7%) 13 (14.0%) 6 (7.8%) 0.114
Cardiac death 4 (1.9%) 1 (1.1%) 0 (0%) 0.588
Any MI 1 (0.5%) 3 (3.2%) 2 (2.6%) 0.093
TLR 6 (2.9%) 18 (19.4%) 8 (10.4%) <0.001
Any revascularization 22 (10.6%) 28 (30.1%) 10 (13.0%) <0.001
Data are presented as number (%). MI, myocardial infarction; Non-TLR, non-target lesion revascularization; OCT, optical coherence tomography; TLR, target lesion
revascularization
https://doi.org/10.1371/journal.pone.0247359.t002
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Discussion
In previous studies, heterogeneous neointima had been closely associated with higher target
lesion failure rates in non-significant lesions not subjected to any interventions [1, 9] and sig-
nificant ISR lesions treated with DCB compared to non-heterogeneous neointima [2, 3]. This
study reported that 1) the incidence of TLR and non-TLR differed according to the in-stent
neointimal characteristics and 2) patients with heterogeneous neointima with DESs were asso-
ciated with a higher incidence of non-TLR and TLR.
Several studies have reported the prediction of cardiovascular events based on the OCT
findings of de novo coronary artery. Thin-cap fibro-atheroma, lipid-rich plaque, and plaque
rupture on OCT are the major risk factors and healed coronary plaque is a preventive factor
for future coronary artery events [10–14]. However, only a few reports have described the
Fig 2. Target lesion revascularization rates (A) and non-target lesion revascularization rates (B) according to the
neointimal characteristics and DCB angioplasty. DCB, drug-coated balloon.
https://doi.org/10.1371/journal.pone.0247359.g002
Table 3. Independent predictors for non-target lesion revascularization.
Variable Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Age 0.988 0.956–1.022 0.487 0.985 0.947–1.023 0.432
Male 0.880 0.450–1.722 0.710 1.240 0.550–2.798 0.604
Diabetes 1.830 0.947–3.536 0.072 1.618 0.796–3.286 0.184
Hypertension 1.284 0.630–2.617 0.492
Dyslipidemia 0.765 0.392–1.494 0.433
Current smoker 1.496 0.735–3.048 0.267
CKD 8.451 2.497–28.606 0.001 8.730 2.175–35.036 0.002
History of MI 3.210 0.756–13.632 0.114
DCB angioplasty after OCT 1.317 0.615–2.823 0.478
First-generation DES 0.986 0.489–1.991 0.970
Homogeneous neointima 0.604 0.310–1.177 0.139
Heterogeneous neointima 2.024 1.025–4.000 0.042 2.237 1.023–4.890 0.044
Layered neointima 0.852 0.349–2.082 0.726
ACEi or ARB 0.891 0.416–1.907 0.766
Beta blocker 0.538 0.269–1.078 0.080 0.901 0.387–2.096 0.809
Statin 1.004 0.303–3.325 0.995
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor antagonist; CKD, chronic kidney disease, CI, confidence interval; DCB, drug-coated
balloon; DES, drug-eluting stent; MI, myocardial infarction; OCT, optical coherence tomography; HR, hazard ratio
https://doi.org/10.1371/journal.pone.0247359.t003
PLOS ONE Neointima and native coronary disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0247359 April 23, 2021 7 / 12
relationship between in-stent neointimal characteristics and non-target lesion outcome. Tani-
waki et al. [15] reported the possible association between in-stent neoatherosclerosis and
native coronary artery disease progression, suggesting similarities in the pathophysiologic
mechanisms of the two entities. Our results also showed that the incidence of non-TLR was
higher in the in-stent heterogeneous neointima group than in non-heterogeneous neointima
groups, particularly homogeneous neointima group. Compared with a previous study, the cur-
rent study focused on neointimal patterns without neoatherosclerotic features. This novel
study suggests that the heterogeneous neointimal pattern without definite neoatherosclerosis
may have clinical implications similar to those of neointima with neoatherosclerosis reported
previously. Moreover, the change in neointimal pattern generally precedes neoatherosclerosis
development, indicating that non-TLR events may be predicted earlier than that reported in a
previous study with neoatherosclerosis. In terms of the possible mechanisms underlying the
development of heterogeneous neointima, inflammation due to hypersensitivity reaction to
drugs or polymers of a DES may play an important role in heterogeneous neointima growth
and in native lesion progression [3]. In this study, the incidence of non-TLR in the heteroge-
neous neointima group with DCB angioplasty was higher than that of non-significant stented
lesion with heterogeneous neointima as well as non-heterogeneous neointima with DCB
angioplasty. This result indicates that atherosclerosis progression in non-stented de novo
lesion may occur more rapidly in significant stented lesion with heterogeneous pattern than in
non-significant lesion with heterogeneous neointima or significant lesion with homogeneous
neointima. Given the important contribution of inflammatory processes to neointimal degen-
eration and native atherosclerosis as a continuity of coronary artery tree, the presence and
extent of neointimal tissue inflammation may affect the atherosclerotic progression of de novo
coronary artery that is not associated with stent [16, 17].
In previous articles, second-generation DES showed better results in intermediate-term
strut apposition and coverage than first-generation DES, as well as superiority in long-term
Table 4. Independent predictors for any revascularization.
Variable Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Age 0.994 0.968–1.020 0.633 0.978 0.950–1.007 0.132
Male 0.643 0.383–1.078 0.094 0.770 0.426–1.392 0.386
Diabetes 1.847 1.111–3.070 0.018 1.524 0.897–2.592 0.119
Hypertension 0.833 0.492–1.411 0.497
Dyslipidemia 0.838 0.499–1.408 0.505
Current smoker 1.259 0.716–2.213 0.424
CKD 6.354 2.253–17.920 <0.001 5.971 1.902–18.751 0.002
History of MI 1.439 0.349–5.927 0.614
DCB angioplasty after OCT 2.430 1.406–4.203 0.001
First-generation DES 1.043 0.609–1.788 0.877
Homogeneous neointima 0.301 0.169–0.537 <0.001 0.505 0.222–1.150 0.104
Heterogeneous neointima 4.324 2.537–7.370 <0.001 2.671 1.261–5.656 0.010
Layered neointima 0.820 0.411–1.637 0.574
ACEi or ARB 0.741 0.417–1.316 0.306
Beta blocker 0.434 0.251–0.752 0.003 0.745 0.403–1.378 0.348
Statin 0.856 0.365–2.006 0.720
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor antagonist; CI, confidence interval; CKD, chronic kidney disease; DCB, drug-coated
balloon; DES, drug-eluting stent; MI, myocardial infarction; OCT, optical coherence tomography; HR, hazard ratio
https://doi.org/10.1371/journal.pone.0247359.t004
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clinical results [18, 19]. However, there have been little investigation dealt with the difference
in DCB angioplasty outcomes between first-generation DES and second-generation DES. In
present study, we did not find a significant difference of TLR rate between first-generation
DES and second-generation DES (TLR rate; 8.7% vs 8.4%, p = 0.924). This finding may reflect
similar efficacy of DCB angioplasty either first-generation or second-generation DES ISR, but
this result should be evaluated with further clinical trials.
The risk factor of heterogeneous neointima formation is not well known. In present study,
clinical presentation of MI at the time of OCT was independent risk factors for the develop-
ment of heterogeneous neointimal tissue. Gonzalo et al. [4] also demonstrated that the inci-
dence of heterogeneous neointima is much higher in patients with unstable angina than those
with stable angina. In our study, in patients with non-TLR, a similar degree of stenosis was
noted among the 3 neointimal patterns at the time of OCT. However, non-TLR occurrence
developed earlier in the in-stent heterogeneous group, which may suggest a rapid progression
of native lesion in this group of neointimal pattern. A possible explanation was shown in
recent cases with OCT evaluation of both stented and native lesions (these cases were not
included in the current analysis; Fig 3).
Although whole vessel OCT examination is expected to provide more accurate information
to assess the association between the stented and native lesions and predict future coronary
events, performing OCT on all coronary arteries is impractical because it requires an excessive
use of contrast agents and increases procedure time. Otherwise, an OCT for stented lesions
may be a more clinically useful method to provide information on lesion progression in native
lesion as well as stented lesion, which can be more practical approach in real clinical practice.
To date, little or no treatment has been known to affect the formation and changes in in-
stent neointimal characteristics. However, a previous study [20] reported that an intensive
lipid control may be beneficial to prevent heterogeneous neointimal degeneration. In the cur-
rent clinical viewpoint, applicable treatment options are limited to reduce a future event in
patients with in-stent heterogeneous neointima, and potent lipid-lowering agents or anti-
inflammatory agents is a possible suggested approach. However, more investigation and data
are warranted to support this concept.
This study has several limitations. First, although the neointima was categorized based on
frames within MLA or greatest neointimal CSA, a single category may not sufficiently repre-
sent the neointima when the lesion was diffused. Second, the study had a heterogeneous popu-
lation because we included all patients who underwent an OCT examination regardless of
Fig 3. Association of in-stent neointimal patterns and native coronary plaque characteristics. Angiographic and
optical coherence tomography images of the in-stent homogeneous neointimal pattern (A, B) and fibrous
atherosclerotic plaque (C, D, E) and the in-stent heterogeneous neointimal pattern (F, G) and thin-cap fibroatheroma
(H, I, J) in the native coronary artery.
https://doi.org/10.1371/journal.pone.0247359.g003
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DCB treatment. Third, time from index PCI to OCT was not constant, and variation among
individuals was noted. Nevertheless, follow-up duration was adequate to assess the effect of
neointimal characteristics and not different among the 3 neointima groups. Fourth, a neointi-
mal pattern with neoatherosclerosis was not included in this analysis which may require fur-
ther study. Finally, even if we provided representative OCT images of the association between
in-stent neointimal pattern and native coronary artery plaque pattern, we did not perform
OCT on all of the non-target lesions. Therefore, we could not completely reveal the difference
of the OCT pattern of non-target lesion depending on the in-stent neointimal characteristics.
Conclusions
Heterogeneous neointima in DES-treated lesion was associated with a higher incidence of
non-TLR and stented target lesion failure. This finding suggests that the neointimal pattern of
DES may be a possible prognostic indicator of native lesion progression.
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